DiabetOmics announced a new point-of-care test to detect preeclampsia, assess the severity of the disease, and monitor its complications in as early as the 1st trimester.

Typically, preeclampsia occurs in the 2nd or 3rd trimester or pregnancy. The test, however, measures a specific protein in maternal blood earlier so that physicians can better assess and monitor the condition as the pregnancy progresses.

A prospective cohort of singleton pregnancies underwent routine 1st trimester screening from 2009–2011 (n=5,759). A regression-based predictive model for early- and late-onset preeclampsia was created based on several factors, including levels of pregnancy-associated plasma protein-A and free beta-human chorionic gonadotropin at 8–12 weeks.

RELATED: Low-Dose Aspirin to Prevent Preeclampsia Recommended

Results showed that at 5% and 10% false-positive rates, detection rates were 69.2% and 80.8% for early preeclampsia (AUC 0.95; 95% CI: 0.94–0.98), and 29.4% and 39.6% for late preeclampsia (AUC 0.71; 95% CI: 0.66–0.76), respectively.

The company plans to make the test available in early 2015.

For more information call (877) 748-9355 or visit DiabetOmics.com.